Mental illness and stigma

Rocha, Fábio Lopes; Hara, Cláudia; Paprocki, Jorge

doi:10.5935/2238-3182.20150127

Cited by 12 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another important issue is the fact that the class of medications analyzed (which act on the nervous system) are mainly used for diseases that are stigmatized (schizophrenia, depression, mood disorders, substance use disorders) by society 19 . This may explain the scarcity of reactions identified, as these diseases are not the target of major studies and investments by the pharmaceutical industry, unlike other diseases such as cancer 20 .…”

Section: Discussionmentioning

confidence: 99%

Alterações laboratoriais dos medicamentos atuantes no sistema nervoso de uma Relação Municipal de Medicamentos Essenciais do nordeste brasileiro

GOMES,

PEREIRA,

DIAS

et al. 2024

Rev Bras Farm Hosp Serv Saude

View full text Add to dashboard Cite

Objetivo: Realizar um levantamento sobre as interferências nos exames laboratoriais dos medicamentos incluídos na classificação Anatomical Therapeutic Chemical (ATC) N (medicamentos que atuam no sistema nervoso), presentes na Relação Municipal de Medicamentos Essenciais (REMUME) do município de Fortaleza, no estado do Ceará. Métodos: Trata-se de uma pesquisa exploratória. Utilizou-se como descritores de busca os nomes dos medicamentos presentes na 3º edição REMUME 2022, nas bases de dados Bulário Eletrônico da Agência Nacional de Vigilância Sanitária e UpToDate®. Em seguida, classificaram-se as interferências laboratoriais identificadas em in vitro e in vivo. Além disso, agruparam-se as alterações in vivo de acordo com a frequência das reações adversas, baseando-se no preconizado pelo Medical Dictionary for Regulatory Activities. Os dados foram compilados e analisados usando o software Microsoft Office Excel® 2013. Resultados: Dos 50 medicamentos analisados, observou-se que 16% não apresentaram nenhuma interferência in vitro e/ou in vivo. As classes terapêuticas que apresentaram mais alterações laboratoriais in vitro foram os anticonvulsivantes (12%, n=6), seguido dos antidepressivos, com 6% (n=3). No que tange às alterações in vivo, os anticonvulsivantes também foram a classe farmacológica com mais alterações (22%, n=11), seguidos também dos antidepressivos (18%, n=9). Biperideno, clobazam, hidroxizina, nicotina, pramipexol, piridostigmina, rivastigmina e rasagilina não apresentaram nenhuma alteração in vitro ou in vivo, de acordo com a literatura consultada. As principais alterações orgânicas envolviam sistema hematológico, com destaque para reações que apresentavam frequência desconhecida. Conclusão: Constatamos que medicamentos da REMUME do município de Fortaleza-CE, utilizados em situações clínicas que envolvem o sistema nervoso central, podem ocasionar alterações laboratoriais. Resultados laboratoriais alterados provocados pelos medicamentos em uso e não pela doença em si, podem vir a comprometer a terapêutica do paciente, gerando condutas médicas errôneas e consequentemente iatrogenias, culminando em mais tempo de hospitalização e gastos para os serviços de saúde.

show abstract

Section: Discussionmentioning

confidence: 99%

Alterações laboratoriais dos medicamentos atuantes no sistema nervoso de uma Relação Municipal de Medicamentos Essenciais do nordeste brasileiro

GOMES,

PEREIRA,

DIAS

et al. 2024

Rev Bras Farm Hosp Serv Saude

View full text Add to dashboard Cite

show abstract

“…According to our analyses, ‘Inclusion of patient representative in the team’ may also be important for the quality of recommendations. Considering patients unique views, preferences and values regarding treatment benefits and harms enriches CPGs, helps minimise disease stigmatisation and improves adherence to treatment 47–50…”

Section: Discussionmentioning

confidence: 99%

Factors associated with higher quality of clinical practice guidelines and their recommendations for the pharmacological treatment of depression: a systematic review

et al. 2023

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to assess the quality of clinical practice guidelines (CPGs) for the pharmacological treatment of depression along with their recommendations and factors associated with higher quality.DesignWe conducted a systematic review that included CPGs for the pharmacological treatment of depression in adults.Data sourcesWe searched for publications from 1 January 2011 to 31 December 2021, in MEDLINE, Cochrane Library, Embase, PsycINFO, BVS and 12 other databases and guideline repositories.Eligibility criteria for selecting studiesWe included CPGs containing recommendations for the pharmacological treatment of depression in adults at outpatient care setting, regardless of whether it met the U.S. National Academy of Medicine criteria, or not. If a CPG included recommendations for both children and adults, they were considered. No language restriction was applied.Data extraction and synthesisData extraction was also conducted independently and in duplicate, a process that was validated in a previous project. The quality of the CPGs and their recommendations were assessed by three independent reviewers using Appraisal of Guidelines for Research and Evaluation (AGREE II) and Appraisal of Guidelines for Research and Evaluation-Recommendations Excellence (AGREE-REX). A CPG was considered to be of high quality if AGREE II Domain 3 was ≥60%; while their recommendations were considered high if AGREE-REX Domain 1 was ≥60%.ResultsSeventeen out of 63 (27%) CPGs were classified as high quality, while 7 (11.1%) had high-quality recommendations. The factors associated with higher-scoring CPGs and recommendations in the multiple linear regression analyses were ‘Handling of conflicts of interest’, ‘Multiprofessional team’ and ‘Type of institution’. ‘Inclusion of patient representative in the team’ was also associated with higher-quality recommendations.ConclusionsThe involvement of professionals from diverse backgrounds, the handling of conflicts of interest, and the inclusion of patients’ perspectives should be prioritised by developers aiming for high-quality CPGs for the treatment of depression.

show abstract

“…People's behavior starts to be seen as unpredictable, fickle and problematic, arouses anguish, fear and anxiety, because it is believed to be facing something unknown, which is out of control, putting professionals in the place of impotence and generating frustration (35) . investment, which implies the deterioration of the health conditions and reduced quality of life (36) .…”

Section: Discussionmentioning

confidence: 99%

Pain in the bipolar disorder: prevalence, characteristics and relationship with suicide risk

Rosa

Leão

2021

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

Objective: to know the prevalence and characteristics of pain, to verify how pain management has been carried out by the health services, and to correlate suicide risk with pain intensity in patients with bipolar disorder. Method: an observational study with a quantitative approach. The study included people with bipolar disorder assessed by the McGill-Reduced Pain Questionnaire, Body Diagram, Visual Numerical Scale, and the Suicidal Ideation Scale (Beck). Results: the sample of 60 participants was mainly composed of women with a mean age of 40 years old and a mean psychiatric treatment time of approximately 13 years. Of these, 83% reported feeling pain at the time of the interview. Half of the participants indicated that pain interferes with routine and 80% did not receive care in health institutions. The main descriptors that qualify the painful experience were as follows: painful, heavy and sensitive for the sensory descriptors, tiring and punishing in the affective category. Suicide attempt was reported by 57% of the participants. There was a correlation between suicide risk and pain intensity. Conclusion: pain presented a high prevalence. Suicide risk was identified in more than half of the participants. Pain intensity showed a significant correlation with suicide risk.

show abstract

Mental illness and stigma

Cited by 12 publications

References 13 publications

Alterações laboratoriais dos medicamentos atuantes no sistema nervoso de uma Relação Municipal de Medicamentos Essenciais do nordeste brasileiro

Alterações laboratoriais dos medicamentos atuantes no sistema nervoso de uma Relação Municipal de Medicamentos Essenciais do nordeste brasileiro

Factors associated with higher quality of clinical practice guidelines and their recommendations for the pharmacological treatment of depression: a systematic review

Pain in the bipolar disorder: prevalence, characteristics and relationship with suicide risk

Contact Info

Product

Resources

About